A61K33/20

ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD

A system and method includes a nonthermal plasma sub-system with a permeable UV filter for production and delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid, and wherein the perfluorocarbon liquid is dispensed onto a gas-permeable membrane and wherein the reactive species may include, alone, or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species, and the perfluorocarbon liquid may include perfluorodecalin.

ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD

A system and method includes a nonthermal plasma sub-system with a permeable UV filter for production and delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid, and wherein the perfluorocarbon liquid is dispensed onto a gas-permeable membrane and wherein the reactive species may include, alone, or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species, and the perfluorocarbon liquid may include perfluorodecalin.

SHELF-STABLE HYPOCHLOROUS ACID
20230017920 · 2023-01-19 ·

The use of powdered or gelled hypochlorous acid (HOCI) in the treatment or prevention of viral and bacterial infection is disclosed.

SHELF-STABLE HYPOCHLOROUS ACID
20230017920 · 2023-01-19 ·

The use of powdered or gelled hypochlorous acid (HOCI) in the treatment or prevention of viral and bacterial infection is disclosed.

TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE
20230218662 · 2023-07-13 ·

The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.

TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE
20230218662 · 2023-07-13 ·

The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.

THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Absorbent aliphatic polyurethane foam product

The present invention relates to foam. In particular, the present invention relates to profiled foams and processes for profiling absorbent foam products. More particularly, the present invention relates to processes for producing a profiled absorbent polyurethane foam product, comprising the steps of foaming, curing, profiling and drying, wherein profiling occurs before drying; and absorbent aliphatic polyurethane foam products having at least one profiled surface.

Absorbent aliphatic polyurethane foam product

The present invention relates to foam. In particular, the present invention relates to profiled foams and processes for profiling absorbent foam products. More particularly, the present invention relates to processes for producing a profiled absorbent polyurethane foam product, comprising the steps of foaming, curing, profiling and drying, wherein profiling occurs before drying; and absorbent aliphatic polyurethane foam products having at least one profiled surface.